Relationship Between Antibodies to *Toxocara* and the Disability of the Human Ankylosing Spondylitis

Francisco-Javier Jiménez-Balderas, Patricia Méndez-Samperio, Raquel Tapia-Romero and Jorge-Luis de-la-Rosa-Arana

Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México D.F., Mexico
Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, México D.F., México
Hospital Infantil de México, Secretaría de Salud, México D.F., México
lnstituto de Diagnóstico y Referencia Epidemiológicos, Secretaría de Salud, México D.F., México

**Abstract:** There are only few studies reported in the literature of patients with spondyloarthropathies associated with *Toxocara* infection. Thus, the aim of this work was to investigate the relationship between antibodies to *Toxocara* and the disability of the human Ankylosing Spondylitis (AS). Thirty-six AS patients (14 female and 22 male) participated during the study period and all were residents from Mexico City. Evaluations included physician and patient self-assessment Bath Ankylosing Spondylitis Functional Index (BASFI) to define the joint limitation of the spine. Blood tests included the identification of Human Leukocyte Antigen B27 (HLA-B27), Erythrocyte Sedimentation Rate (ESR), levels of C-Reactive Protein (CRP) and levels of antibodies to *Toxocara canis* and *Ascaris lumbricoides*. Seventy seven serum samples of healthy donors were used as control group. Seropositivity for *T. canis* was detected in 25% of patients with AS and 1/36 was positive for antibodies to *Ascaris* while, 2/77 were positive for *Toxocara* and 1/77 for *Ascaris* in the control group. A correlation between antibodies to *Toxocara* and the presence of AS was observed (p=0.0005432; Mid-P exact, two tails); the levels of antibodies to *Toxocara* were not associated with the HLA-B-57 antigen neither with the disability caused by the AS, although the 74% of AS patients had high values of BASFI (6.4±1.5) with normal levels of CRP and ESR. In addition, no significant difference was observed between the AS patients and control group in the seropositivity for *Ascaris* (p = 0.64). These results suggest a minor role for toxocariosis in the AS limited joint in Mexican population, however further studies are needed to determine the role of *Toxocara* in the AS prognosis.

**Keywords:** Ankylosing-spondylitis, *Toxocara*, Antibodies, Mexico

**Introduction**

Ankylosing Spondylitis (AS) is an inflammatory disease of unknown etiology, affecting mainly the axial skeleton and adjacent structures as well as involvement of multiple organs including the eyes, lungs and heart (Sieper et al., 2006; Zochling, 2008). In addition, AS is the most severe subtype of spondyloarthritis (Anderson et al., 2001). Although several studies have described the relationship between disease activity in patients with AS and bacterial infections, including infections by *Salmonella* (Paul et al., 1988; Martinez et al., 2004) and *Yersinia* (Yli-Kerttula et al., 1995), there are few reported cases of rheumatic syndromes associated with parasitic infections (Bocanegra and Vasey, 1993; Peng, 2002). In this regard, it has been demonstrated arthritis associated to the infection by the nematode *Toxocara* (Williams and Roy, 1981; Kuk et al., 2006; Jiménez-Balderas et al., 2012). The main species that causes human toxocariosis are *T. canis* and *T. cati*, the former associated to dogs and the second to cats. The adult worm lives in the intestinal gut of puppies and, the excrete eggs become infective in the soil after 1-3 weeks.
Humans become infected by oral ingestion of the infectious eggs (Magnaual et al., 2001). A high prevalence of antibodies to Toxocara has been found in countries where the dog population is abundant (Oge and Oge, 2000; Radman et al., 2000). In Mexico, dogs and cats are commonly used as pets (Romero-Núñez et al., 2013). Since many patients with active AS are dog owners, our aim was to investigate whether there is a relationship between antibodies to Toxocara and the disability of the ankylosing spondylitis in Mexican patients.

Materials and Methods

Subjects

The present study enrolled 36 consecutive adult patients (14 female and 22 male; mean ± SD age: 39.7±15.1 years) with a diagnosis of definite AS. Patients were clinically diagnosed in a tertiary health care hospital. All patients fulfilled the 1984 modified New York criteria for diagnosis of AS (Calin et al., 1994; Garrett et al., 1994) and completed questionnaires assessing functional ability Bath Ankylosing Spondylitis Functional Index (BASFI). This questionnaire includes 10 questions; eight evaluate activities related to the condition of the spine and two questions evaluate the patient’s ability to cope with daily life (normal value ≤4, range 0-10). In the course of their medical appointment, each patient was invited to participate in this study; only patients with residence in urban areas and with a frequent clinical follow up was included. Patients with other spondyloarthropathies or hepatitis B or C were excluded.

No symptoms or signs of Toxocara infection were identified at this point. Initial assessment included collection of demographic information by questionnaire. Those patients with other spondyloarthropathies or hepatitis B or C were excluded. The control group was formed by 77 samples from healthy individuals (46 female and 31 male; mean ± SD age: 30±15 years).

Methodology

A total of 5 ml of blood sample were collected from each patient. Serum samples were separated and then stored at -20°C. Blood tests included the identification of human leukocyte antigen B27 (HLA-B27), Erythrocyte Sedimentation Rate (ESR; Wintrobe, normal value 0-20 mm/h) and, C-Reactive Protein (CRP; immunoturbidimetry method Roche/Hitachi 912, Roche Diagnostic Corporation, Indianapolis, IN, USA, normal value ≤10 mg/L), Antibodies to Toxocara canis or Ascaris lumbricoides antigens were determined by an in-house Enzyme-Linked Immunosorbent Assay (ELISA). Antibodies to Toxocara and Ascaris were determined in order to discard unspecific results by the cross-reaction between antigens. Assays were performed as previously described (Jiménez-Balderas et al., 2012). Briefly, antigens were prepared of adult worms collected from natural infections. A crude extract was prepared from A. lumbricoides and the excretory and secretory products were obtained from Toxocara canis. Soluble antigens were diluted at 0.003 mg/mL in 100 mM carbonate-bicarbonate buffer, pH 9.6. Flat-bottom polystyrene plates (Corning-Costar, Tewksbury, MA, USA) were coated with 0.1 mL/well of antigen solution then, incubated overnight at 4°C. After remove the antigen solution, the plate was washed three times with 0.1 mL/well of 1% nonfat milk during 2 h at 37°C. After washing, the enzyme reaction was repeated. Anti-human IgG-horseradish peroxidase conjugate (Zymed-Aldrich, St. Louis, MO, USA) and H2O2 dissolved in 75 mM phosphate-citrate buffer, pH 5 and, 0.1 ml was added to each well. The enzyme reaction was terminated with 0.1 mL/well of 2 M H2SO4. Absorbency values were determined at 490 nm. The serological parameters (e.g., cut off, sensitivity and specificity) were previously calculated and reported. Respect to the serological parameters for Ascaris assay, sensitivity was of 90.90%, specificity 98.70% and cutoff 0.45 while, for Toxocara sensitivity was 80.77, specificity 97.40 and cutoff 0.35 (Jiménez-Balderas et al., 2012).

Statistical Analysis

The Mid-p exact tests as well as the Odds Ratio (OR) and their 95% Confidence Intervals (CI) between patients were used to analyze group differences. Otherwise, statistical analysis was performed using the statistical package Epi-Epidemiology ver. 2 (http://www.openepi.com). A p-value <0.05 was considered significant. The linear regression and the student’s T test were also used to determine the correlation between the level of antibodies to helminthes and the ESR and CPR parameters.

Results

Data regarding the demographic characteristics of Ankylosing Spondylitis (AS) patients are show in Table 1. The mean ± SD age of all patients was of 39.7±15.1 years and, the mean ± SD age at onset of disease was of 24.6±11.6 years; the disease duration was 14.6±13.6
years. At the time of the study, 35/36 patients were administered with anti-inflammatory non-steroidal drugs; additionally, 15/36 patients were administered only with one drug (3 with etanercept, 11 with sulfasalazine [SSZ] and 1 with methotrexate [MTX]), 5/36 with two drugs (3 with MTX + SSZ, 2 with SSZ + etanercept) and 1/36 patient with 3 drugs (MTX + SSZ + etanercept). Specific IgG antibodies to Toxocara were determined in 25% (9/36) of the AS serum samples and, for Ascaris in 2.7% (1/36) of the samples. The positive sample for Ascaris was no positive for Toxocara. In the healthy group the seropositive was of 2.59% and 1.3% respectively. A correlation of AS and antibodies to Toxocara were observed (p=0.0005432; Mid-p exact, two tails. Odds Ratio: 2.703-87.27) but, the level of antibodies was not associated with the disability of AS (BASFI, CRP or ESR) neither to the HLA-B27 antigen (Table 2). The HLA-B27 antigen was positive in 62.5% (20/32) of AS patients, which 7 were female and 13 were male; no data about HLA-B27 antigen were available in 4 AS patients. No correlation was observed between the presence of HLA-B27 antigen and the presence of antibodies to Toxocara (0.6265; Mid-P exact, two tails). The BASFI was elevated in 74% of AS patients (6.4±1.5; normal value ≤4, range 0-10), but no correlation was observed between the BASFI and the levels of antibodies to Toxocara (0.3708; Mid-P exact, two tails). The mean value of the Erythrocyte Sedimentation Rate (ESR) was of 16.9±12.8 mm/h which was according to the normal values (0-20 mm/h), since average values in healthy men are <15 mm/h and, in healthy females, they are somewhat higher, <20 mm/h. Although some AS patients have ESR over the normal values, no differences were observed between AS patients with or without antibodies to Toxocara (p = 0.1058; Student’s T test). The mean value of C-reactive protein in the AS patients was of 6.8±4.2 (normal value ≤10 mg/L), no differences were between AS patients with or without antibodies to Toxocara (p = 0.0600; Student’s T test).

Evaluation of Ankylosing Spondylitis (AS) discapacity included the patient self-assessment Bath Ankylosing Spondylitis Functional Index (BASFI), identification of human leukocyte antigen B27 (HLA-B27), Erythrocyte Sedimentation Rate (ESR) and levels of C-Reactive Protein (CRP). LR = Linear Regression.

Discussion

Human toxocariosis, usually caused by Toxocara canis, is an important health problem in developing countries (Magnaval et al., 2001). Data here obtained show that seropositivity to Toxocara in patients with AS is 25%, which is in accordance with the observation that the seroprevalence of toxocariosis varies between 1.8 to 58.3% depending on country (Macpherson, 2013). In addition, our results show a T. canis seroprevalence of 2.59% in the control group. The above discrepancies may be due to the fact that the seroprevalence of toxocariosis varies depending on country.

| Table 1. Demographic characteristics of ankylosing spondylitis patients |
|---------------------------------------------------------------|
| AS patients (n = 36)                              | Healthy group (n = 77)                     |
| Gender (female/male)                             | 14/22                                      | 31/46                                      |
| Mean ± SD age                                    | 39.7±15.1                                   | 30±15                                      |
| Mean ± SD age at onset of AS                     | 24.6±11.6                                   | ---                                        |
| Disease duration (years)                         | 14.6±13.6                                   | ---                                        |
| Toxocara seropositive (+/–)                      | (9/36)*                                    | (2/77)                                     |
| Ascaris seropositive (+/–)                       | (1/36)                                     | (1/77)                                     |

*Statistical differences were calculated with the Mid-p exact, two tails (p = 0.0005432), Odds Ratio CMLE value = 12.18 (2.703- 87.27)

| Table 2. Relationship between the ankylosing spondylitis disability and the level of antibodies to Toxocara |
|----------------------------------------------------------------------------------------------------------------|
| Group mean                                                                 | Antibodies to Toxocara                                                                 | Statistical data                                                                 |
| HLA-B27 (n = 32)                                                              | Positive (n = 20) | Negative (n = 12) | 0.6265 | 0.119 |
| BASFI                                                                 | 5.3±2.2         | 6.6±2.7          | 5.1±2.1 | 0.3708 |
| Student’s T test                                                                 |                                                                                       |
| CRP (mg/L)                                                                  | 6.8±4.2         | 4.0±2.5          | 7.4±3.3 | 0.06  | 0.0052 |
| ESR (mm/h)                                                                   | 16.9±12.8       | 26.2±12.2        | 14.8±12.2 | 0.1058 | 0.2345 |

*Data were no available in four patients

Evaluation of Ankylosing Spondylitis (AS) discapacity included the patient self-assessment Bath Ankylosing Spondylitis Functional Index (BASFI), identification of human leukocyte antigen B27 (HLA-B27), Erythrocyte Sedimentation Rate (ESR) and levels of C-Reactive Protein (CRP). LR = Linear Regression
Since data about the relationship between antibodies to Toxocara and the disability of ankylosing spondylitis are scarce, we decide to study a limited number of AS patients in an exploratory form. Although it is known that the analysis of small samples provide limited conclusions also, it is known that a limited number of AS patients are attending in a tertiary health care hospital. At this level of care, the number of AS patients is over 150 per year and, only 40% of them are urban residents and have a frequent follow-up (F.J. Jimenez-Balderas, unpublished data). The limited number of AS cases in medical attendance is explained considering that in Mexico there are no systematic studies regarding on the prevalence and distribution of AS. The AS prevalence is estimated with basis on the prevalence of HLA-B27 antigen, i.e., between 0.5 and 1% (Burgos-Vargas et al., 2009). Thus, in accordance with the Mexican population estimated in 2013 (119,000,000 inhabitants), a proportion of 0.005 to 0.01 AS patients cases per capita (equivalent to one case for each 100 to 200 inhabitants) is estimated, which is a low frequency compared with the 7.5% prevalence of diabetes mellitus in adults (Olaz-Fernández et al., 2007).

In México, T. canis is the most common ascarid in dogs but in humans, the infecting nematode larvae are unable to complete their own developmental life cycle and propagation (Hotez and Wilkins, 2009). The clinical symptoms vary as a consequence of larvae migration, ranging from asymptomatic forms to those with severe organ injuries (Overgaauw and van-Knapen, 2013). The observation that our patients never had a clinical picture of systemic toxocariasis and has normal eosinophil counts is consistent with previous reports showing that most patients with systemic toxocariasis are asymptomatic (Despommier, 2003). These data are also in perfect accordance with a previous report showing that the absence of eosinophilia does not exclude toxocariasis (Taylor et al., 1988). In the absence of parasitological evidence of infection, immunological methods play a relevant role in the diagnosis of toxocariasis. Currently, the diagnosis of toxocariasis is made by detection of antibodies directed against the T. canis antigens using the sensitive technique ELISA (Elefant et al., 2006). In this study, we use an ELISA previously standardized by us, the serological parameters were of 80.77% for diagnostic sensitivity and 97.40% for specificity (Jiménez-Balderas et al., 2012).

Although Western blotting procedure could be more suitable for the serological diagnosis of toxocariasis, the ELISA has been particularly recommended in seroepidemiological studies (Radman et al., 2000; Elefant et al., 2006). Further studies are needed to determine the reactivity of AS serum samples by Western blotting to identify the existence of patterns that could be used in diagnosis. Indeed it would be helpfulness, determine the presence of serological antigens to determine active infections.

During the evolution of the asymptomatic toxocariasis, the detection of antibodies against the T. canis depends on the number of infecting larvae (Despommier, 2003). In this study, the detected antibodies in some AS patients, show that these patients were in contact with the parasite, however no symptoms of toxocariasis was clinical observed during the study.

There are only sporadic reports on the relationship between disease activity and parasitic infection in patients with rheumatologic syndromes. Williams and Roy (1981) have reported a case of arthritis associated with Toxocara infection. Furthermore, Peng (2002) has reported that potential parasitosis must be considered in patients with rheumatic syndromes. More recently, data from Richter et al., (2006) have found that in some individuals arthritis may be due to helminthes, such as Strongyloides stercoralis. A study conducted by Kuk et al. (2006) reported 3.2% Toxocara seropositivity in AS patients. These studies indicate that in some rheumatic manifestations parasitic infection may underlie the clinical presentation. Although in this study, Toxocara positivity was higher than in the control group, the levels of antibodies to Toxocara were not associated with the HLA-B-57 antigen neither with the disability caused by the AS, although the 74% of AS patients had high values of BASFI (6.4±1.5) with normal levels of CRP and ESR. Additionally, our data demonstrated no significant difference in the seroprevalence to A. lumbricoides (which has a higher frequency of cross-reaction with T. canis) when compared between in AS patients and control group. At present, there are no published data on this issue from a group of Mexican patients. These data may represent an important report, since no systematic reports about incidence of toxocariasis is found in Mexico. Toxocara investigations should be undertaken to determine whether our AS patients have risk factors for parasitic infection, such as their immunocompromised state and frequent contacts with dogs at home.

In conclusion, we investigated the possible association between the AS disease and the presence of antibodies to Toxocara in Mexican patients. We found that Toxocara seroprevalence was higher in patients with AS than in healthy individuals but antibodies were not associate to HLA-B-57 antigen neither with the disability caused by the AS. Our results suggest a minor role of toxocariasis involved in the pathology of the AS in Mexico but since limited conclusions could be obtained with the analysis of small samples further larger-scale studies are needed to determine the role of Toxocara in the AS prognosis.

Acknowledgment

We would like to express our gratitude to the staff at Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social for their helpfulness during this study. P. Méndez-Samperio is a fellow in the programs of
Stimuli Researchers Performance and, Operation and Development Committee of Academic Activities, National Politecnic Institute, in addition to the program of National System of Researchers, National Council of Science and Technology. J.-L. de-la-Rosa-Arana is a fellow at the National System of Researchers, National Council of Science and Technology.

Author’s Contributions

All authors equally contributed in this work.

Ethic

This article is original and contains unpublished material. The corresponding author confirms that all of the other authors have read and approved the manuscript and no ethical issues involved.

References

Anderson, J.J., G. Baron, D. van der Heijde, D.T. Felson and M. Dougados, 2001. Ankylosing spondylitis assessment group preliminary definition of short-term improvement inkylosing spondylitis. Arthritis Rheum., 44: 1876-1886. DOI: 10.1002/1529-0131(200108)

Bocanegra, T.S. and F.B. Vasey, 1993. Musculoskeletal syndromes in parasitic diseases. Rheum. Dis. Clin. North Am., 19: 505-513. PMID: 8502785

Burgos-Vargas, R., C. Abud-Mendoza, E. Díaz-Jouanen, M.A. Garza-Elizondo and G. Medrano-Ramirez et al., 2009. Fundamentos para el tratamiento de la espondilitis anquilosante y su efecto en la reumatología mexicana. Gac. Méd. Méx., 145: 41-49.

Calin, A., S. Garrett, H. Whitelock, L.G. Kennedy and J. O’Hea et al., 1994. A new approach to defining functional ability inkylosing spondylitis: The development of the bath ankylosing spondylitis functional index. J. Rheumatol., 21: 2281-2285. PMID: 7699629

Despommier, D., 2003. Toxocariasis: Clinical aspects, epidemiology, medical ecology and molecular aspects. Clin. Microbiol. Rev., 16: 265-272. DOI: 10.1128/CMR.16.2.265-272.2003

Elefant, G.R., S.H. Shimizu, M.C. Arroyo-Sánchez, C.M. Abe-Jacob and A.W. Ferreira, 2006. A serological follow-up of toxocariasis patients after chemotherapy based on the detection of IgG, IgA and IgE antibodies by enzyme-linked immunosorben assay. J. Clin. Lab. Anal., 20: 164-172. DOI: 10.1002/jcla.20126

Garrett, S., T. Jenkinson, L.G. Kennedy, H. Whitelock and P. Gaisford et al., 1994. A new approach to defining disease status in ankylosing spondylitis: The bath ankylosing spondylitis disease activity index. J. Rheumatol., 21: 2286-2291. PMID: 7699630

Hotez, P.J. and P.P. Wilkins, 2009. Toxocariasis: America’s most common neglected infection of poverty and a helminthiasis of global importance? PLoS Negl. Trop. Dis., 3: e400- e400. DOI: 10.1371/journal.pntd.0000400

Jiménez-Balderas, F.J., A. Camargo-Coronel, J. García-Jaines, A. Zonana-Nacach and I. Alcantara-Anguiano et al., 2012. A study on parasites in Mexican rheumatic disease patients. J. Egypt Soc. Parasitol., 42: 271-280. PMID: 23214207

Kuk, S., S. Ozgocmen and S. Bulut, 2006. Seroprevalence of Toxocara antibodies in multiple sclerosis and ankylosing spondylitis. Indian J. Med. Sci., 60: 297-299. DOI: 10.4103/0019-5359.26605

Macpherson, C.N., 2013. The epidemiology and public health importance of toxocariasis: A zoonosis of global importance. Int. J. Parasitol., 43: 999-1008. DOI: 10.1016/j.ijpara.2013.07.004

Magnaual, J.F., L.T. Glickman, P. Dorchies and B. Morassini, 2001. Highlights of human toxocariasis. Korean J. Parasitol., 39: 1-11. DOI: 10.3347/kjp.2001.39.1.1

Martinez, A., C. Pacheco-Tena, J. Vázquez-Mellado and R. Burgos-Vargas, 2004. Relationship between disease activity and infection in patients with spondyloarthropathies. Ann. Rheum. Dis., 63: 1338-1340. DOI: 10.1136/ard.2003.011882

Oge, S. and H. Oge, 2000. Prevalence of Toxocara spp.eggs in the soil of public parks in Ankara, Turkey. Dtsch. Tierarzt. Wochenschr, 107: 72-75. PMID: 10743338

Olaiz-Fernández, G., R. Rojas, C.A. Aguilar-Salinas, J. Rauda and S. Villalpando, 2007. Diabetes mellitus en adultos mexicanos. Resultados de la Encuesta Nacional de Salud 2000. Salud Pública Méx., 49: S331-S337. DOI: 10.1590/S0036-36342000000900004

Overgaard, P.A. and F. van-Knapen, 2013. Veterinary and public health importance of toxocariasis: A zoonosis of global importance. Int. J. Parasitol., 43: 57-63. DOI: 10.1016/j.ijpara.2013.07.004

Paul, I.R., E.S. Mitchell and A.L. Bell, 1988. The epidemiology and public health aspects of Toxocara spp. Vet. Parasitol., 193: 398-403. DOI: 10.1016/j.vetpar.2012.12.035

Peng, S.L., 2002. Rheumatic manifestations of parasitic diseases. Semin. Arthritis Rheum., 31: 228-247. PMID: 11836656

Radman, N.E., S.M. Archelli, R.D. Fonrouge, M. del VGuardis and O.R. Linzitto, 2000. Human toxocariasis. Its seroprevalence in the city of La Plata. Mem. Inst. Oswaldo Cruz, 95: 281-285. DOI: 10.1590/S0074-02762000000300001

Richter, J., I. Müller-Stöver, H. Strothmeyer, K. Göbels and M. Schmitt et al., 2006. Arthritis associated with Strongyloides stercoralis infection in HLA B-27-positive African. Parasitol. Res., 99: 706-707. DOI: 10.1007/s00436-006-0225-9
Romero-Núñez, C., G.D. Mendoza-Martínez, S. Yáñez-Arteaga, M. Ponce-Macotela and P. Bustamante-Montes et al., 2013. Prevalence and risk factors associated with *Toxocara canis* infection in children. Scientific World J., 2013: 572089-572089. DOI: 10.1155/2013/572089

Sieper, J., M. Rudwaleit, M.A. Khan and J. Braun, 2006. Concepts and epidemiology of spondyloarthritis. Best Pract. Res. Clin. Rheumatol., 20: 401-417. DOI: 10.1016/j.berh.2006.02.001

Taylor, M.R., C.T. Keane, P. O’Connor, E. Mulvihill and C. Holland, 1988. The expanded spectrum of *toxocaral* disease. Lancet, 1: 692-695. PMID: 2895221

Williams, D. and S. Roy, 1981. Arthritis and arthralgia associated with *toxocaral* infestation. Br. Med. J., 283: 192-192. DOI: 10.1136/bmj.283.6285.192

Yli-Kerttula, T., R. Tertti and A. Toivanen, 1995. Ten-year follow up study of patients from a *Yersinia* pseudotuberculosis III outbreak. Clin. Exp. Rheumatol., 13: 333-337. PMID: 755456

Zochling, J., 2008. Assessment and treatment of ankylosing spondylitis: Current status and future directions. Curr. Opin. Rheumatol., 20: 398-403. DOI: 10.1097/BOR.0b013e3283028328